Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide—yet early detection dramatically improves survival rates. Despite the proven effectiveness of colonoscopy, many delay or avoid it due to its invasive nature. That delay can be costly.

To bridge the gap between risk and action, a new non-invasive tool has emerged. Colon AiQ, developed by Genekor and introduced to the region by Med Surg Solutions, uses liquid biopsy technology to detect molecular changes linked to colorectal cancer—long before symptoms appear. It offers a reliable, simple, and highly accurate alternative for those hesitant about colonoscopy.

How It Works

Colon AiQ analyzes cfDNA (circulating free DNA) from a blood sample, examining the methylation profile of five clinically validated genetic regions. These profiles shift in the presence of colorectal cancer—even in precancerous stages like advanced adenomas—making early diagnosis possible.

A Smarter First Step

Colon AiQ is ideal for:
● Individuals delaying colonoscopy
● High-risk patients needing more frequent, interim screening
● Anyone 45+ seeking non-invasive screening, per global guidelines

Based on molecular blood analysis, Colon AiQ is the most accurate non-invasive colorectal cancer screening test in Europe, providing an essential early detection tool.

Why Choose Colon AiQ?

● Unmatched Accuracy: Sensitivity 86%, Specificity 92%
● Detects Advanced Adenomas early—critical for prevention
● Simple & Stress-Free: Just one blood draw, no prep needed
● Clinically Validated: Supported by large-scale studies (200,000+ participants)

Colon AiQ is redefining colorectal cancer screening—offering an effective solution for those who hesitate, and a proactive pathway for early intervention. Backed by clinical evidence and powered by innovation, it’s a step toward more personalized, accessible cancer care.

At Med Surg Solutions, we’re proud to be part of this transformation toward smarter, simpler, and more effective screening.